Extended Data Table 1 Summary of primary and secondary outcome data

From: Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial

  1. Overview of the primary and secondary outcomes for single-infusion patients versus controls. Values shown are baseline, day 90 and baseline to day 90 change for each outcome measure in both single-infusion and control groups. Significance was computed using two-sided, two-sample t-tests, controlling for equal variance as indicated. Significance for INR was computed using two-sided Fisher’s exact test. MELD, model for end-stage liver disease; UKELD, United Kingdom model for end-stage liver disease; ALT, alanine aminotransferase; INR, international normalized ratio; ELF, enhanced liver fibrosis test; VCTE, vibration controlled transient elastography.
Back to article page